Close Menu

The $1,000 genome won't do any good for science if researchers can't interpret it, says Adina Mangubat, CEO of Spiral Genetics, in Xconomy. While industry has focused most of its time and energy to creating better ways to sequence a genome, it has "largely ignored the computational power required to extract and analyze the genomic data in a timeframe that keeps it relevant," Mangubat adds. And most labs aren't prepared for all that data.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.